Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 118, Issue 39, Pages -Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.2015243118
Keywords
glioblastoma; neuroblastoma; proliferation; LRH1; agonists
Categories
Funding
- Hellenic Foundation for Research and Innovation (H.F.R.I.) [1782]
- ARISTEIA-II [4786]
- Fondation Sante Biomedical Research grants
Ask authors/readers for more resources
Nervous system malignancies exhibit rapid progression and low survival rates. NR5A2, identified as a negative regulator of cancer cell proliferation, shows potential as a pharmacological target for nervous system-related tumors. High expression levels of NR5A2 are associated with a favorable prognosis in patients with glioblastoma and neuroblastoma, with the antiproliferative effect of NR5A2 mediated by the induction of negative regulators of the cell cycle. Agonists of NR5A2, such as DLPC, mimic its antiproliferative action in glioblastoma cells and inhibit tumor growth in mouse models. These findings suggest a tumor suppressor role of NR5A2 in the nervous system, highlighting its potential as a therapeutic target for nervous tissue-related tumors.
Nervous system malignancies are characterized by rapid progression and poor survival rates. These clinical observations underscore the need for novel therapeutic insights and pharmacological targets. To this end, here, we identify the orphan nuclear receptor NR5A2/LRH1 as a negative regulator of cancer cell proliferation and promising pharmacological target for nervous system-related tumors. In particular, clinical data from publicly available databases suggest that high expression levels of NR5A2 are associated with favorable prognosis in patients with glioblastoma and neuroblastoma tumors. Consistently, we experimentally show that NR5A2 is sufficient to strongly suppress proliferation of both human and mouse glioblastoma and neuroblastoma cells without inducing apoptosis. Moreover, short hairpin RNA-mediated knockdown of the basal expression levels of NR5A2 in glioblastoma cells promotes their cell cycle progression. The antiproliferative effect of NR5A2 is mediated by the transcriptional induction of negative regulators of the cell cycle, CDKN1A (encoding for p21cip1), CDKN1B (encoding for p27kip1) and Prox1. Interestingly, two well-established agonists of NR5A2, dilauroyl phosphatidylcholine (DLPC) and diundecanoyl phosphatidylcholine, are able to mimic the antiproliferative action of NR5A2 in human glioblastoma cells via the induction of the same critical genes. Most importantly, treatment with DLPC inhibits glioblastoma tumor growth in vivo in heterotopic and orthotopic xenograft mouse models. These data indicate a tumor suppressor role of NR5A2 in the nervous system and render this nuclear receptor a potential pharmacological target for the treatment of nervous tissue-related tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available